Newswise — Could we finally have a faster, more objective analytical tool to rapidly measure viral infectivity for vaccine development and production? Scientists and bioengineers at Thermo Fisher Scientific and LumaCyte believe we do. This peer reviewed work will be published on September 12th in the prestigious journal, Vaccine, by Elsevier, detailing how LumaCyte’s RadianceTM instrument, based on Laser Force Cytology (LFC), offers researchers the ability to rapidly analyze viral vaccines to speed development and production and ensure their effectiveness.
Many viral vaccines use live infectious viruses to generate an immune response that later protects vaccinated individuals from a new infection with the same or similar virus. Thus, the measurement of infectious virus concentration is critical for vaccine safety and efficacy and is used throughout R&D, biomanufacturing, release testing, and clinical trials. Current techniques for measuring viral infectivity are generally slow, labor-intensive and difficult to standardize, which often creates a bottleneck in the development process and makes it more difficult to respond to emerging and rapidly-changing threats such as Ebola, Zika Virus, and Influenza.
Rapid viral quantification during a response to an emerging infectious disease or pandemic is especially important as delays in vaccine production can hamper efforts to contain the spread of a new pandemic. Many existing systems for viral quantification rely on fluorescently tagged antibodies (labels), that for new viruses could require many months to a year or more to develop and test thoroughly. LumaCyte’s label-free Radiance instrument appears to offer significant improvement over label-based methods and can further enhance researchers’ efforts against these growing threats.
In the study, the authors demonstrate two scenarios for improved detection of viral infection of vesicular stomatitis virus (VSV) in a mammalian cell line. VSV is commonly used for vaccine production including several candidate vaccines against emerging infectious diseases such as the Ebola, Lassa, and Nipah viruses. The first is for cells that are already infected with VSV during an ongoing bioprocess that can be analyzed immediately using Radiance (5-10 min instrumental process and analysis time) representing a ∼400 to 800-fold reduction in the time required to obtain an answer (72 hours in the conventional end-point dilution process). This capability is truly game changing as Radiance offers researchers real-time monitoring of viral infectivity, something which currently is not possible using standard techniques. This allows near real-time process control and monitoring, which is incredibly valuable for the vaccine industry that is expected to hit $114B in 2028.
In the second scenario, rapid viral infectivity determination for crude or purified virus solutions, where samples of the preparation can be taken, applied to suspension or adherent cells and then incubated for a 3-7X shorter period (depending on the virus and cells used) before automated analysis using Radiance. The authors showed how VSV infectivity measurements based upon LFC and Radiance were more sensitive and yielded results in 16 hours versus the 72 hours required using conventional method, endpoint dilution. In addition to the shorter incubation period, the results do not rely on operator interpretation and require less labor, further reducing costs.
LumaCyte’s Radiance™ instrument is a label-free automated high content cell analyzer and sorter that measures the optical force, size, shape, deformability, and captures images of single cells. By measuring intrinsic biophysical and biochemical properties of single cells, cellular changes due to viral infection can be rapidly, repeatably, and objectively quantitated. LFC is very sensitive to agents that perturb cellular structures or change biochemical composition. High quality viral infectivity measurements can be made in a fraction of the time, labor, and cost of traditional assays such as plaque or endpoint dilution or in near real-time throughout the infection process.
“Rapid Quantification of Vesicular Stomatitis Virus in Vero cells using Laser Force Cytology”, Colin G. Heberta, Nicole DiNardob, Zachary L. Evansa, Sean J. Harta, and Anna-Barbara Hachmannb* https://www.sciencedirect.com/science/article/pii/S0264410X(18)312374 It appears in Vaccine, Volume 36, Issue 41 (2018), Published by Elsevier.
aLumaCyte, LLC. 1145 River Road, Suite 16, Charlottesville, VA 22901, USA
bThermo Fisher Scientific, Inc., 3175 Staley Road, Grand Island, NY 14072, USA
Link to journal website: www.elsevier.com/locate/vaccine
Copies of this paper are available to credentialed journalists upon request; please contact Elsevier's Newsroom at [email protected] or +31 20 485 2719
About Vaccine
Vaccine is the pre-eminent journal for those interested in vaccines and vaccination. It is the official journal of The Edward Jenner Society and The Japanese Society for Vaccinology and is published by Elsevier www.elsevier.com/locate/vaccine
About Thermo Fisher Scientific
Thermo Fisher Scientific is the world leader in serving science, with revenues of more than $20 billion and approximately 70,000 employees globally. Our mission is to enable our customers to make the world healthier, cleaner and safer. We help our customers accelerate life sciences research, solve complex analytical challenges, improve patient diagnostics, deliver medicines to market and increase laboratory productivity. Through our premier brands – Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific and Unity Lab Services – we offer an unmatched combination of innovative technologies, purchasing convenience and comprehensive services.
About LumaCyte
LumaCyte is an advanced research and analytics instrumentation company headquartered in Charlottesville, VA. LumaCyte produces label-free, single cell analysis and sorting instrumentation where the use of antibody or genetic labelling is not required for cellular analysis. This revolutionary technology utilizes optical forces within a microfluidic channel to identify and measure the intrinsic cellular properties of each cell. Applications of LumaCyte’s label-free platform technology include viral infectivity for vaccine development and manufacturing, cancer biology R&D, CAR-T, cell therapy, iPSCs, infectious disease, and pre-clinical drug discovery, with multiple applications for use in manufacturing and quality control for process optimization.
RSS